GastroAGI Logo
OverviewBlogsAbout
Trending TopicsConference
Topics/Endoscopy/A new horizon of endoscopic anti-reflux therapy

A new horizon of endoscopic anti-reflux therapy

Clinical knowledge base curated and reviewed by GastroAGI TeamLast updated September 1, 2025

Quick Answer

The new horizon of endoscopic anti-reflux therapy is exemplified by the emergence of Anti-Reflux Mucosal (ARM) interventions, which include anti-reflux mucosectomy (ARMS), mucosal ablation (ARMA), and mucoplasty (ARMP). These techniques represent a groundbreaking advancement in the minimally invasive treatment of gastroesophageal reflux disease (GERD), particularly for patients who remain symptomatic despite pharmacologic therapy.


The new horizon of endoscopic anti-reflux therapy is exemplified by the emergence of Anti-Reflux Mucosal (ARM) interventions, which include anti-reflux mucosectomy (ARMS), mucosal ablation (ARMA), and mucoplasty (ARMP). These techniques represent a groundbreaking advancement in the minimally invasive treatment of gastroesophageal reflux disease (GERD), particularly for patients who remain symptomatic despite pharmacologic therapy. ARM therapies aim to bridge the gap between long-term acid suppression with medications and invasive surgical options like Nissen fundoplication.

### Key Features and Innovations in Endoscopic Anti-Reflux Therapy:

1. **Rationale for Development**:

  • GERD is a prevalent condition, and approximately 30–40% of patients continue to experience symptoms despite the use of proton pump inhibitors (PPIs) or potassium-competitive acid blockers (PCABs).
  • ARM techniques were developed to provide a cost-effective, incisionless, and minimally invasive alternative for patients with drug-refractory GERD who do not have large hiatal hernias or major esophageal motility disorders.

2. **Mechanism of Action**:

  • ARM procedures rely on mucosal removal or modification to induce ulceration, followed by controlled healing at the gastroesophageal junction (GEJ). This healing process leads to shrinkage and tightening of the GEJ, reconstructing the natural mucosal flap valve and enhancing its anti-reflux barrier function.

3. **Specific Techniques**:

  • **Anti-Reflux Mucosectomy (ARMS)**: Involves mucosal resection to induce controlled scarring and tightening of the GEJ. Long-term data show symptom improvement in 68–81% of patients and PPI discontinuation in 42%.
  • **Anti-Reflux Mucosal Ablation (ARMA)**: A simpler variant of ARMS that uses argon plasma coagulation instead of resection. It achieves clinical response rates exceeding 70% with measurable improvements in reflux metrics.
  • **Anti-Reflux Mucoplasty (ARMP)**: A more advanced technique that closes mucosal defects during the initial session, providing immediate anti-reflux effects and reducing risks of delayed ulcer healing or bleeding.

4. **Technical Innovations**:

  • Tools such as prong clips, loop-assisted systems, and hand suturing have enabled full-thickness closure, involving mucosa, submucosa, and muscle fibers, to reinforce the anti-reflux flap valve.
  • The development of the "angle booster" accessory improves endoscopic access and visualization of the cardia, enhancing procedural precision.
  • The counter-mucosal incision technique prevents dehiscence during mucosal closure, ensuring durable valve tightening.

5. **Clinical Outcomes**:

  • ARM interventions have demonstrated success rates of 70–82% in terms of symptom relief and PPI discontinuation.
  • Minor complications, such as transient dysphagia (11%) and bleeding (5%), are typically manageable endoscopically, with no major life-threatening complications reported in meta-analyses.

6. **Comparative Effectiveness**:

  • ARM techniques show comparable efficacy to radiofrequency ablation and Nissen fundoplication, with the added benefits of shorter recovery times, reduced postoperative discomfort, and lower costs.
  • ARMP provides controlled tightening and immediate symptom relief, making it a preferred option for patients with naïve anatomy, while ARMA is suited for redo cases or patients with submucosal fibrosis.

7. **Application Beyond GERD**:

  • The mucoplasty principle is being explored for other gastrointestinal conditions, such as treating multiple Schatzki’s rings. This represents the first functional "endoscopic plastic surgery" approach in gastrointestinal disease.

8. **Future Directions**:

  • Research is focusing on the long-term durability of ARM techniques, standardization of ulcer dimensions for optimal tightening, incorporation of full-thickness suturing, and cost-effectiveness comparisons with surgical options like Nissen fundoplication and magnetic sphincter augmentation.

### Conclusion:

Endoscopic anti-reflux therapy, particularly ARM interventions, has redefined the treatment landscape for GERD. These techniques offer a minimally invasive, anatomy-tailored approach that provides significant symptom relief (70–82%) with minimal complications. By addressing the limitations of pharmacologic therapy and offering an alternative to surgery, ARM therapies represent a promising new horizon in the individualized management of GERD.

Related Q&A

EndoBarrier Improves Diabetes and Weight Loss: Ann Surg | July 2026

Introduction: Endoscopic metabolic therapies have emerged as less invasive alternatives to bariatric surgery for patients with obesity and poorly controlled type 2 diabetes mellitus (T2DM). The EndoBarrier duodenal-jejunal bypass liner (DJBL) is an endoscopically placed...

Immediate Endoscopic Necrosectomy in Necrotizing Pancreatitis: Gastroenterology | July 2026

Introduction: Endoscopic ultrasound (EUS)-guided transmural drainage is the standard minimally invasive treatment for symptomatic necrotizing pancreatitis. However, the optimal timing of direct endoscopic necrosectomy (DEN) following drainage remains uncertain. While the conventional step-up approach reserves...

Endoscopy After Bevacizumab Appears Safe: GIE | July 2026

Introduction: Bevacizumab is widely used in metastatic colorectal cancer (mCRC) because of its survival benefits but is associated with impaired wound healing, gastrointestinal perforation, and bleeding. These concerns often lead clinicians to delay endoscopic procedures...

Colorectal ESD Perforation: Endoscopy | July 2026

Introduction: Endoscopic submucosal dissection (ESD) enables en bloc resection of large colorectal neoplasms with excellent oncological outcomes. However, concerns about perforation have limited its widespread adoption. This large prospective multicenter study evaluated the incidence, risk...

Duodenal Mucosal Resurfacing REMAIN-1 Study: DDW | 2026

Introduction: Obesity has become one of the greatest global health challenges. New incretin-based therapies—including semaglutide, tirzepatide, resmetirom, and SGLT2 inhibitors such as empagliflozin—have transformed the treatment of obesity, diabetes, and MASLD. However, many patients discontinue...

EUS-FNAB for Solid Pancreatic Lesions: GIE | July 2026

Introduction: Endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB) is the standard technique for diagnosing solid pancreatic lesions. Traditionally, biopsy specimens are processed for cytology, often requiring on-site cytopathology support. This multicenter prospective study evaluated whether directly placing...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersSoonFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer